Now showing items 1-1 of 1

  • A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease 

    Wun, Ted; Soulieres, Denis; Frelinger, Andrew L; Krishnamurti, Lakshmanan; Novelli, Enrico M; Kutlar, Abdullah; Ataga, Kenneth I; Knupp, Charles L; McMahon, Lillian E; Strouse, John J; Zhou, Chunmei; Heath, Lori E; Nwachuku, Chuke E; Jakubowski, Joseph A; Riesmeyer, Jeffrey S; Winters, Kenneth J (2013-02)
    Background Platelet activation has been implicated in the pathogenesis of sickle cell disease (SCD) suggesting antiplatelet agents may be therapeutic. To evaluate the safety of prasugrel, a thienopyridine antiplatelet ...